Health Care & Life Sciences » Biotechnology | Iris Biotechnologies Inc.

Iris Biotechnologies Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2011
2012
2013
2014
2015
Cash & Short Term Investments
43.70
1.00
19.00
322.90
19.80
Other Current Assets
-
14.70
-
-
3.60
Total Current Assets
43.70
15.80
19.00
322.90
23.50
Net Property, Plant & Equipment
23.00
9.00
4.20
8.90
29.60
Long-Term Note Receivable
128.40
-
128.40
128.40
128.40
Total Assets
195.10
24.70
151.60
460.20
181.50
ST Debt & Current Portion LT Debt
-
-
45.00
5.00
-
Accounts Payable
34.80
96.80
146.00
-
-
Other Current Liabilities
-
-
0.20
237.20
468.60
Total Current Liabilities
34.80
96.80
191.20
242.20
468.60
Long-Term Debt
-
47.00
16.00
26.00
26.00
Total Liabilities
34.80
143.80
207.20
268.20
494.60
Common Equity (Total)
160.30
119.10
55.70
192.00
313.10
Total Shareholders' Equity
160.30
119.10
55.70
192.00
313.10
Total Equity
160.30
119.10
55.70
192.00
313.10
Liabilities & Shareholders' Equity
195.10
24.70
151.60
460.20
181.50

About Iris Biotechnologies

View Profile
Address
5201 Great America Parkway
Santa Clara California 95054
United States
Employees -
Website http://www.irisbiotech.com
Updated 07/08/2019
Iris Biotechnologies, Inc. is a life sciences company focused on health care. It offers the best approach to the treatment of cancer and other diseases through actionable integration of molecular profiling in the clinical decision-making process. The Iris Nano-Biochip product pipeline include CancerChip, PrenatalChip, Integrated Blood Test, IVF applications, NeuroChip, MetabolicChip, CardioChip, and Chips for veterinary, agricultural, environmental, and other applications.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.